A Phase 2/3 interventional study of tucatinib and trastuzumab in Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma and Esophageal Adenocarcinoma, sponsored by Seagen Inc.. Completed at 48 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-22.
Sponsored by Seagen Inc. (part of Pfizer) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 246 studies in Adenocarcinoma Of Esophagus with a site in United States — 53 open to participants now, 73 under way, 7 of them phase 3. Adenocarcinoma Of Esophagus · United States.
Among the 246 studies in Adenocarcinoma Of Esophagus with a site in United States, this one is the 166th largest by enrollment of the 203 interventional ones that give a count, is one of 8 that started in 2021, is one of 5 in phase 2/3, and was the 180th registered.
354 studies on the registry are indexed under Adenocarcinoma Of Esophagus; 81 are open to participants now.
Browse Adenocarcinoma Of Esophagus studies →53 of the 246 studies in Adenocarcinoma Of Esophagus with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Case Comprehensive Cancer Center · Sites in United States
Ages 18+
Yale University · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 70 Adenocarcinoma Of Esophagus studies recruiting now, 60 (86%) set no upper age limit and 2 (3%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
246 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 56 · Phase 2 150 · Phase 3 18 · Phase 4 2
First in 1995; this study’s year is marked. 8 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 51 across 277 interventional studies indexed under Adenocarcinoma Of Esophagus.
Median enrollment 49 across the 203 interventional studies, 155 across the 23 observational. Of the 156 that completed or were terminated, 63 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 246 have an industry lead sponsor. The 10 most frequent:
This study is registered under Seagen Inc., one of the names counted as Pfizer. Under that name alone:
Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.
Pfizer has 6 studies filed under Adenocarcinoma Of Esophagus — fewer than ten, so there is no comparison to draw.
18 of the studies in Adenocarcinoma Of Esophagus with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06203600Phase 3National Cancer Institute (NCI)Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | 2027-10-31 |
| NCT02962063Memorial Sloan Kettering Cancer CenterDurvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer | 2026-11 |
| NCT06532734Denver Health and Hospital AuthorityBarrett's Esophagitis in Anorexia Nervosa Binge/Purge Subtype | 2026-11 |
| NCT07023731Arvinas Inc.A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation | 2026-11-30 |
| NCT04900818I-Mab Biopharma US LimitedStudy of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors | 2026-12 |
Add all 18 to your calendar (.ics) → With an account.
Among the 246 studies in Adenocarcinoma Of Esophagus with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being done to see if tucatinib with trastuzumab, ramucirumab and paclitaxel works better than ramucirumab and paclitaxel to treat HER2-positive (HER2+) cancer of the gut (stomach or gastroesophageal cancer). This study will also look at what side effects happen when participants take this combination of drugs. A side effect is anything the drug does other than treating cancer.
Study treatment will be given in 28-day cycles.
In the Phase 2 part of the trial, participants and their doctors will know what drugs are being given (open-label). In the Phase 3 part, the study is "blinded." This means that participants, their doctor, and the study sponsor will not know which drugs are being given.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
HER2+ disease documented since progression of the most recent , as follows:
Phase 2 paclitaxel dose optimization stage:
Phase 2 dose expansion stage:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tucatinib + trastuzumab + ramucirumab + paclitaxel
Drug: tucatinib · Drug: trastuzumab · Drug: ramucirumab · Drug: paclitaxel
Tucatinib + trastuzumab + ramucirumab + paclitaxel
Drug: tucatinib · Drug: trastuzumab · Drug: ramucirumab · Drug: paclitaxel
Ramucirumab + paclitaxel + tucatinib placebo + trastuzumab placebo
Drug: ramucirumab · Drug: paclitaxel · Other: tucatinib placebo · Other: trastuzumab placebo
Tucatinib + ramucirumab + paclitaxel + trastuzumab placebo
Drug: tucatinib · Drug: ramucirumab · Drug: paclitaxel · Other: trastuzumab placebo
300 mg given twice daily orally
Also known as: TUKYSA, ONT-380, ARRY-380
6 mg/kg loading dose will be administered intravenously (IV; into the vein) on Cycle 1 Day 1, followed by 4 mg/kg IV on Cycle 1 Day 15 and then Days 1 and 15 of each cycle thereafter
8 mg/kg will be administered IV on Days 1 and 15 of each cycle
Also known as: CYRAMZA
60 or 80 mg/m\^2 IV on Days 1, 8, and 15 of each cycle
Given twice daily orally
IV on Days 1 and 15 of each cycle
Number of Participants With Dose-limiting Toxicities (DLT) During the First Cycle of Treatment
DLTs were adverse events (AEs), laboratory abnormalities, or treatment modifications that occurred during the first cycle of treatment in the Phase 2 paclitaxel dose optimization stage that were related to paclitaxel, to tucatinib, or to the combination of tucatinib, trastuzumab, ramucirumab and paclitaxel and that met any of the study protocol specified criteria. The relationship of AEs to study drugs was determined by the investigator. AEs that were attributed only to trastuzumab and/or ramucirumab, but not tucatinib or paclitaxel were not considered DLTs.
Time frame: Cycle 1 (28 days)
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An AE was any untoward medical occurrence in a participant or clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. AEs were defined as treatment emergent if they were newly occurring or worsened following study treatment. A TEAE was defined as a newly occurring or worsening AE after the first dose of study treatment (tucatinib, trastuzumab, ramucirumab, or paclitaxel) and up to 30 days after the last dose of study treatment (tucatinib, trastuzumab, ramucirumab, or paclitaxel, whichever was later).
Time frame: From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum treatment duration= 19.8 months, maximum follow-up duration up to 20.8 months)
Number of Participants With Treatment-emergent Laboratory Abnormalities
Treatment-emergent laboratory abnormalities were defined as abnormalities that are new or worsened on or after receiving the first dose of study treatment up to 30 days after the last dose of study treatment. Laboratory abnormalities included: 1) Blood chemistry: alanine aminotransferase increased, albumin decreased, alkaline phosphatase increased, aspartate aminotransferase increased, calcium corrected for albumin decreased, calcium corrected for albumin increased, creatinine increased, glomerular filtration rate estimated decreased, glucose decreased, lactate dehydrogenase increased, magnesium decreased, magnesium increased, potassium decreased, potassium increased, sodium decreased, sodium increased, and total bilirubin increased; 2) Hematological: hemoglobin decreased, leukocytes decreased, lymphocytes decreased, neutrophils decreased, and platelets decreased.
Time frame: From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum treatment duration= 19.8 months, maximum follow-up duration up to 20.8 months)
Number of Participants With Clinically Significant Vital Signs Values
Vital sign examinations included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate. Criteria: SBP greater than or equal to (\>=) 120 millimeters of mercury (mm Hg) or DBP \>= 80 mm Hg; SBP \>= 140 mm Hg or DBP \>= 90 mm Hg; SBP \>= 160 mm Hg or DBP \>= 100 mm Hg), heart rate greater than (\>) 100 beats per minute (min). Clinical significance in vital signs abnormalities was judged by investigator. In this outcome measure number of participants with at least 1 clinically significant abnormality in any vital sign are reported.
Time frame: From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum treatment duration= 19.8 months, maximum follow-up duration up to 20.8 months)
Maximum Percentage Change From Baseline in Weight
Maximum percentage decrease from baseline in weight is reported in this outcome measure.
Time frame: From Baseline (Day 1) up to 30 days after the last dose of study treatment (maximum treatment duration= 19.8 months, maximum follow-up duration up to 20.8 months)
Number of Participants With Any Dose Modifications
Dose modification included dose hold, dose reduction, dose error and unplanned dose adjustments. Number of participants with any dose treatment modifications for paclitaxel, ramucirumab, trastuzumab, and tucatinib are reported in this outcome measure.
Time frame: From first dose of the study treatment (Day 1) up to the last dose of study treatment (maximum treatment duration up to 19.8 months)
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 By Investigator Assessment
ORR was defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR) according to RECIST v 1.1 by investigator assessment. As per RECIST v1.1, CR was defined as disappearance of all target and non-target lesions and normalization of tumor markers. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm). PR was defined as at least a 30 % decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. As per RECIST v1.1, disease progression (PD) was defined as one of the following: at least a 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) with an absolute increase of at least 5mm, unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions.
Time frame: From the first dose of study treatment until the first documented CR or PR on or before the first documented PD or new anti-cancer therapies or death, whichever occurred first (up to 19.8 months)
Confirmed ORR Per RECIST v1.1 By Investigator Assessment
Confirmed ORR was defined as the percentage of participants with best overall response of confirmed CR or PR according to RECIST v1.1 by investigator assessment. For a response to be confirmed, the subsequent response needs to be at least 4 weeks after the initial response. As per RECIST v1.1, CR was defined as disappearance of all target and non-target lesions and normalization of tumor markers. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30 % decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. As per RECIST v1.1, disease progression (PD) was defined as one of the following: at least a 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) with an absolute increase of at least 5mm, unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions.
Time frame: From the first dose of study treatment until the first documented confirmed CR or PR or before the first documented PD or new anti-cancer therapies or death, whichever occurred first (up to 19.8 months)
Progression-Free Survival (PFS) Per RECIST v1.1 By Investigator Assessment
PFS was defined as the time from the date of treatment initiation to the date of documented PD or death from any cause, whichever occurred first per RECIST version 1.1 by investigator assessment. As per RECIST v1.1, disease progression (PD) was defined as one of the following: at least a 20% increase in the sum of diameters (SOD) of target lesions (taking as reference the smallest sum on study) with an absolute increase of at least 5mm, unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions. Participants without documentation of PD or death at the time of analysis were censored at the date of the last tumor assessment. Kaplan-Meier method was used for evaluation.
Time frame: From the date of first dose until the first documentation of PD or death or censoring date, whichever occurred first (up to 19.8 months)
Duration of Response (DOR) Per RECIST v1.1 By Investigator Assessment
DOR: time from first documentation of objective response of CR or PR to first documentation of PD or death from any cause, whichever occurred first according to RECIST v1.1 by investigator assessment. As per RECIST v1.1, CR: disappearance of all target and non-target lesions and normalization of tumor markers. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10mm. PR: at least a 30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. PD was defined as one of the following: at least a 20% increase in sum of diameters of target lesions (taking as reference the smallest sum on study) with an absolute increase of at least 5mm, unequivocal progression of existing non-target lesions, or appearance of one or more new lesions. Participants without documentation of PD or death at time of analysis were censored at the date of last tumor assessment. Kaplan-Meier method was used for evaluation.
Time frame: From the first documented CR or PR until the first documentation of PD or death or censoring date, whichever occurred first (up to 19.8 months)
Disease Control Rate (DCR) Per RECIST v1.1 By Investigator Assessment
DCR was defined as percentage of participants with CR, PR, or stable disease (SD or non-CR/non-progressive disease) according to RECIST v1.1 by investigator assessment. As per RECIST v1.1, CR was defined as disappearance of all target and non-target lesions and normalization of tumor markers. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30 % decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. PD was defined as one of following: at least a 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) with an absolute increase of at least 5mm, unequivocal progression of existing non-target lesions, or appearance of one or more new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum of diameters.
Time frame: From the first dose study treatment until PD or death, whichever occurred first (up to 19.8 months)
Area Under the Plasma Concentration-time Curve to the Time of the Last Quantifiable Concentration (AUClast) of Paclitaxel, Tucatinib and Their Metabolites
AUClast was reported for tucatinib, tucatinib metabolite (ONT-993), paclitaxel and paclitaxel metabolites (6 alpha-hydroxy-paclitaxel, 3'-p-hydroxy-paclitaxel and 6 alpha-3'-p-Dihydroxy-paclitaxel).
Time frame: Tucatinib and ONT-993- Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 2, 4, 6, 8 hours post-dose; Paclitaxel and its metabolites- Cycle 1 Days 1 and 8, Cycle 2 Day 1: Pre-dose, 2, 4, 6, 8 hours post-dose (each cycle length=28 days)
Maximum Observed Plasma Concentration (Cmax)
Cmax was reported for tucatinib and tucatinib metabolite ONT-993.
Time frame: Tucatinib and ONT-993- Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 2, 4, 6, 8 hours post-dose (each cycle length=28 days)
Time to Maximum Observed Plasma Concentration (Tmax)
Tmax was reported for tucatinib and tucatinib metabolite ONT-993.
Time frame: Tucatinib and ONT-993- Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 2, 4, 6, 8 hours post-dose (each cycle length=28 days)
Trough Concentration (Ctrough)
Ctrough was calculated for tucatinib and tucatinib metabolite ONT-993.
Time frame: Tucatinib and ONT-993- Cycle 1 Day 8, Cycle 2 Day 1: Predose (each cycle length=28 days)
Metabolite Ratio Based on AUClast (MRAUClast)
MRAUClast was defined as metabolic ratio, that is, ratio of the AUClast of a given paclitaxel metabolite over the AUClast of paclitaxel. MRAUClast for 6 alpha-hydroxypaclitaxel, 3-p-hydroxy-paclitaxel and 6 alpha-3-p-dihydroxy-paclitaxel was reported in this outcome measure.
Time frame: Paclitaxel and its metabolites- Cycle 1 Days 1 and 8, Cycle 2 Day 1: Pre-dose, 2, 4, 6, 8 hours post-dose (each cycle length=28 days)
Participants with locally-advanced unresectable or metastatic human epidermal growth factor receptor 2 positive (HER2+) gastric or gastroesophageal junction adenocarcinoma (GEC) who had received prior treatment with a HER2-directed antibody, and had received 1 prior line of therapy in the advanced disease setting were included in the study. A total of 17 participants were enrolled and treated in the study.
| Milestone | Paclitaxel 60 mg/m^2 | Paclitaxel 80 mg/m^2 |
|---|---|---|
| Started | 8 | 9 |
| Completed | 3 | 0 |
| Not completed | 5 | 9 |
| Withdrew: Study termination by sponsor | 4 | 6 |
| Withdrew: Withdrawal by subject | 1 | 3 |
DLTs were adverse events (AEs), laboratory abnormalities, or treatment modifications that occurred during the first cycle of treatment in the Phase 2 paclitaxel dose optimization stage that were related to paclitaxel, to tucatinib, or to the combination of tucatinib, trastuzumab, ramucirumab and paclitaxel and that met any of the study protocol specified criteria. The relationship of AEs to study drugs was determined by the investigator. AEs that were attributed only to trastuzumab and/or ramucirumab, but not tucatinib or paclitaxel were not considered DLTs.
| Participants | Paclitaxel 60 mg/m^2 | Paclitaxel 80 mg/m^2 |
|---|---|---|
| Number of Participants With Dose-limiting Toxicities (DLT) During the First Cycle of Treatment | 0 | 2 |
An AE was any untoward medical occurrence in a participant or clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. AEs were defined as treatment emergent if they were newly occurring or worsened following study treatment. A TEAE was defined as a newly occurring or worsening AE after the first dose of study treatment (tucatinib, trastuzumab, ramucirumab, or paclitaxel) and up to 30 days after the last dose of study treatment (tucatinib, trastuzumab, ramucirumab, or paclitaxel, whichever was later).
| Participants | Paclitaxel 60 mg/m^2 | Paclitaxel 80 mg/m^2 |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 8 | 9 |
Treatment-emergent laboratory abnormalities were defined as abnormalities that are new or worsened on or after receiving the first dose of study treatment up to 30 days after the last dose of study treatment. Laboratory abnormalities included: 1) Blood chemistry: alanine aminotransferase increased, albumin decreased, alkaline phosphatase increased, aspartate aminotransferase increased, calcium corrected for albumin decreased, calcium corrected for albumin increased, creatinine increased, glomerular filtration rate estimated decreased, glucose decreased, lactate dehydrogenase increased, magnesium decreased, magnesium increased, potassium decreased, potassium increased, sodium decreased, sodium increased, and total bilirubin increased; 2) Hematological: hemoglobin decreased, leukocytes decreased, lymphocytes decreased, neutrophils decreased, and platelets decreased.
| Participants | Paclitaxel 60 mg/m^2 | Paclitaxel 80 mg/m^2 |
|---|---|---|
| Hemoglobin decreased | 3 | 7 |
| Leukocytes decreased | 4 | 9 |
| Lymphocytes decreased | 2 | 8 |
| Neutrophils decreased | 5 | 7 |
| Platelets decreased | 1 | 7 |
| Alanine aminotransferase increased | 5 | 5 |
| Albumin decreased | 4 | 4 |
| Alkaline phosphatase increased | 2 | 0 |
| Aspartate aminotransferase increased | 6 | 4 |
| Calcium corrected for albumin decreased | 1 | 5 |
| Calcium corrected for albumin increased | 0 | 2 |
| Creatinine increased | 3 | 2 |
| Glomerular filtration rate, estimated decreased | 0 | 1 |
| Glucose decreased | 1 | 2 |
| Lactate dehydrogenase increased | 1 | 5 |
| Magnesium decreased | 0 | 7 |
| Magnesium increased | 0 | 1 |
| Potassium decreased | 1 | 6 |
| Potassium increased | 1 | 0 |
| Sodium decreased | 2 | 4 |
| Sodium increased | 1 | 1 |
| Total bilirubin increased | 3 | 2 |
Vital sign examinations included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate. Criteria: SBP greater than or equal to (\>=) 120 millimeters of mercury (mm Hg) or DBP \>= 80 mm Hg; SBP \>= 140 mm Hg or DBP \>= 90 mm Hg; SBP \>= 160 mm Hg or DBP \>= 100 mm Hg), heart rate greater than (\>) 100 beats per minute (min). Clinical significance in vital signs abnormalities was judged by investigator. In this outcome measure number of participants with at least 1 clinically significant abnormality in any vital sign are reported.
| Participants | Paclitaxel 60 mg/m^2 | Paclitaxel 80 mg/m^2 |
|---|---|---|
| SBP >= 120 mm Hg or DBP >= 80 mm Hg | 8 | 9 |
| SBP >= 140 mm Hg or DBP >= 90 mm Hg | 7 | 9 |
| SBP >= 160 mm Hg or DBP >= 100 mm Hg | 2 | 3 |
| Heart rate > 100 beats per min | 1 | 4 |
Maximum percentage decrease from baseline in weight is reported in this outcome measure.
| Percent Change | Paclitaxel 60 mg/m^2 | Paclitaxel 80 mg/m^2 |
|---|---|---|
| Maximum Percentage Change From Baseline in Weight | 0.34 (-4.3 to 9.9) | 6.21 (-4.8 to 21.0) |
Dose modification included dose hold, dose reduction, dose error and unplanned dose adjustments. Number of participants with any dose treatment modifications for paclitaxel, ramucirumab, trastuzumab, and tucatinib are reported in this outcome measure.
| Participants | Paclitaxel 60 mg/m^2 | Paclitaxel 80 mg/m^2 |
|---|---|---|
| Paclitaxel | 7 | 9 |
| Ramucirumab | 7 | 8 |
| Trastuzumab | 7 | 8 |
| Tucatinib | 6 | 8 |
ORR was defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR) according to RECIST v 1.1 by investigator assessment. As per RECIST v1.1, CR was defined as disappearance of all target and non-target lesions and normalization of tumor markers. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm). PR was defined as at least a 30 % decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. As per RECIST v1.1, disease progression (PD) was defined as one of the following: at least a 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) with an absolute increase of at least 5mm, unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions.
| Percentage of participants | Paclitaxel 60 mg/m^2 | Paclitaxel 80 mg/m^2 |
|---|---|---|
| Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 By Investigator Assessment | 50.0 (15.7 to 84.3) | 100.0 (66.4 to 100.0) |
Confirmed ORR was defined as the percentage of participants with best overall response of confirmed CR or PR according to RECIST v1.1 by investigator assessment. For a response to be confirmed, the subsequent response needs to be at least 4 weeks after the initial response. As per RECIST v1.1, CR was defined as disappearance of all target and non-target lesions and normalization of tumor markers. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30 % decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. As per RECIST v1.1, disease progression (PD) was defined as one of the following: at least a 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) with an absolute increase of at least 5mm, unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions.
| Percentage of participants | Paclitaxel 60 mg/m^2 | Paclitaxel 80 mg/m^2 |
|---|---|---|
| Confirmed ORR Per RECIST v1.1 By Investigator Assessment | 37.5 (8.5 to 75.5) | 100.0 (66.4 to 100.0) |
PFS was defined as the time from the date of treatment initiation to the date of documented PD or death from any cause, whichever occurred first per RECIST version 1.1 by investigator assessment. As per RECIST v1.1, disease progression (PD) was defined as one of the following: at least a 20% increase in the sum of diameters (SOD) of target lesions (taking as reference the smallest sum on study) with an absolute increase of at least 5mm, unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions. Participants without documentation of PD or death at the time of analysis were censored at the date of the last tumor assessment. Kaplan-Meier method was used for evaluation.
| Months | Paclitaxel 60 mg/m^2 | Paclitaxel 80 mg/m^2 |
|---|---|---|
| Progression-Free Survival (PFS) Per RECIST v1.1 By Investigator Assessment | 4.1 (1.5 to 12.5) | 12.2 (7.0 to 14.4) |
DOR: time from first documentation of objective response of CR or PR to first documentation of PD or death from any cause, whichever occurred first according to RECIST v1.1 by investigator assessment. As per RECIST v1.1, CR: disappearance of all target and non-target lesions and normalization of tumor markers. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10mm. PR: at least a 30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. PD was defined as one of the following: at least a 20% increase in sum of diameters of target lesions (taking as reference the smallest sum on study) with an absolute increase of at least 5mm, unequivocal progression of existing non-target lesions, or appearance of one or more new lesions. Participants without documentation of PD or death at time of analysis were censored at the date of last tumor assessment. Kaplan-Meier method was used for evaluation.
| Months | Paclitaxel 60 mg/m^2 | Paclitaxel 80 mg/m^2 |
|---|---|---|
| Duration of Response (DOR) Per RECIST v1.1 By Investigator Assessment | 10.6 (2.8 to NA) | 11.0 (2.9 to 12.9) |
DCR was defined as percentage of participants with CR, PR, or stable disease (SD or non-CR/non-progressive disease) according to RECIST v1.1 by investigator assessment. As per RECIST v1.1, CR was defined as disappearance of all target and non-target lesions and normalization of tumor markers. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30 % decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. PD was defined as one of following: at least a 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) with an absolute increase of at least 5mm, unequivocal progression of existing non-target lesions, or appearance of one or more new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum of diameters.
| Percentage of participants | Paclitaxel 60 mg/m^2 | Paclitaxel 80 mg/m^2 |
|---|---|---|
| Disease Control Rate (DCR) Per RECIST v1.1 By Investigator Assessment | 87.5 (47.3 to 99.7) | 100.0 (66.4 to 100.0) |
AUClast was reported for tucatinib, tucatinib metabolite (ONT-993), paclitaxel and paclitaxel metabolites (6 alpha-hydroxy-paclitaxel, 3'-p-hydroxy-paclitaxel and 6 alpha-3'-p-Dihydroxy-paclitaxel).
| Hour*nanograms per milliliter | Paclitaxel 60 mg/m^2 | Paclitaxel 80 mg/m^2 |
|---|---|---|
| Cycle 1 Day 8: Tucatinib | 4210 ± 37.7 | 3210 ± 60.0 |
| Cycle 1 Day 8: ONT-993 | 550 ± 65.3 | 521 ± 92.1 |
| Cycle 2 Day 1: Tucatinib | 2810 ± 34.7 | 3130 ± 35.8 |
| Cycle 2 Day 1: ONT-993 | 348 ± 10.1 | 423 ± 50.4 |
| Cycle 1 Day 1: Paclitaxel | 2180 ± 45.5 | 3500 ± 10.1 |
| Cycle 1 Day 1: 6 alpha-hydroxy-paclitaxel | 118 ± 117 | 133 ± 100 |
| Cycle 1 Day 1: 3'-p-hydroxy-paclitaxel | 49.7 ± 123 | 77.8 ± 40.8 |
| Cycle 1 Day 1: 6 alpha-3'-p-dihydroxy-paclitaxel | 38.9 ± 194 | 42.0 ± 242 |
| Cycle 1 Day 8: Paclitaxel | 2210 ± 54.6 | 3220 ± 41.5 |
| Cycle 1 Day 8: 6 alpha-hydroxy-paclitaxel | 92.7 ± 109 | 155 ± 88.3 |
| Cycle 1 Day 8: 3'-p-hydroxy-paclitaxel | 11.7 ± 106 | 24.3 ± 89.6 |
| Cycle 1 Day 8: 6 alpha-3'-p-dihydroxy-paclitaxel | 7.56 ± 175 | 14.1 ± 128 |
| Cycle 2 Day 1: Paclitaxel | 2380 ± 45.9 | 3120 ± 31.4 |
| Cycle 2 Day 1: 6 alpha-hydroxy-paclitaxel | 51.2 ± 56.9 | 136 ± 116 |
| Cycle 2 Day 1: 3'-p-hydroxy-paclitaxel | 11.3 ± 77.0 | 24.5 ± 97.5 |
| Cycle 2 Day 1: 6 alpha-3'-p-dihydroxy-paclitaxel | 5.48 ± 251 | 12.6 ± 250 |
Cmax was reported for tucatinib and tucatinib metabolite ONT-993.
| Nanograms per milliliter (ng/mL) | Paclitaxel 60 mg/m^2 | Paclitaxel 80 mg/m^2 |
|---|---|---|
| Cycle 1 Day 8: Tucatinib | 769 ± 30.9 | 615 ± 56.1 |
| Cycle 2 Day 1: Tucatinib | 482 ± 21.4 | 553 ± 52.3 |
| Cycle 1 Day 8: ONT-993 | 112 ± 65.2 | 130 ± 99.9 |
| Cycle 2 Day 1: ONT-993 | 79.0 ± 35.7 | 84.2 ± 80.3 |
Tmax was reported for tucatinib and tucatinib metabolite ONT-993.
| Hours | Paclitaxel 60 mg/m^2 | Paclitaxel 80 mg/m^2 |
|---|---|---|
| Cycle 1 Day 8: Tucatinib | 3.5 (2.0 to 6.6) | 3.9 (1.7 to 7.5) |
| Cycle 2 Day 1: Tucatinib | 3.0 (1.4 to 4.9) | 3.9 (1.5 to 5.9) |
| Cycle 1 Day 8: ONT-993 | 1.2 (1.0 to 2.2) | 1.9 (1.0 to 3.9) |
| Cycle 2 Day 1: ONT-993 | 1.3 (1.1 to 2.0) | 2.8 (1.1 to 4.0) |
Ctrough was calculated for tucatinib and tucatinib metabolite ONT-993.
| Nanograms per milliliter (ng/mL) | Paclitaxel 60 mg/m^2 | Paclitaxel 80 mg/m^2 |
|---|---|---|
| Cycle 1 Day 8: Tucatinib | 71.0 ± 2010 | 156 ± 64.3 |
| Cycle 2 Day 1: Tucatinib | 67.4 ± 1180 | 62.0 ± 1320 |
| Cycle 1 Day 8: ONT-993 | 9.64 ± 289 | 17.4 ± 75.7 |
| Cycle 2 Day 1: ONT-993 | 8.23 ± 203 | 8.45 ± 251 |
MRAUClast was defined as metabolic ratio, that is, ratio of the AUClast of a given paclitaxel metabolite over the AUClast of paclitaxel. MRAUClast for 6 alpha-hydroxypaclitaxel, 3-p-hydroxy-paclitaxel and 6 alpha-3-p-dihydroxy-paclitaxel was reported in this outcome measure.
| Ratio | Paclitaxel 60 mg/m^2 | Paclitaxel 80 mg/m^2 |
|---|---|---|
| Cycle 1 Day 1: 6 alpha-hydroxypaclitaxel | 0.0532 ± 92.5 | 0.0373 ± 104 |
| Cycle 1 Day 1: 3-p-hydroxypaclitaxel | 0.0224 ± 99.4 | 0.0218 ± 43.0 |
| Cycle 1 Day 1: 6 alpha-3-p-dihydroxypaclitaxel | 0.0172 ± 151 | 0.0115 ± 269 |
| Cycle 1 Day 8: 6 alpha-hydroxypaclitaxel | 0.0412 ± 67.3 | 0.0474 ± 130 |
| Cycle 1 Day 8: 3-p-hydroxypaclitaxel | 0.00519 ± 78.3 | 0.00741 ± 101 |
| Cycle 1 Day 8: 6 alpha-3-p-dihydroxypaclitaxel | 0.00330 ± 130 | 0.00445 ± 205 |
| Cycle 2 Day 1: 6 alpha-hydroxypaclitaxel | 0.0212 ± 47.9 | 0.0428 ± 120 |
| Cycle 2 Day 1: 3-p-hydroxypaclitaxel | 0.00467 ± 33.1 | 0.00772 ± 78.0 |
| Cycle 2 Day 1: 6 alpha-3-p-dihydroxypaclitaxel | 0.00222 ± 108 | 0.00340 ± 304 |
Collected over From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum treatment duration= 19.8 months, maximum follow-up duration up to 20.8 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Paclitaxel 60 mg/m^2 | 3/8 (37.5%) | 4/8 (50%) | 8/8 (100%) |
| Paclitaxel 80 mg/m^2 | 0/9 (0%) | 5/9 (55.6%) | 9/9 (100%) |
| Event | Paclitaxel 60 mg/m^2 | Paclitaxel 80 mg/m^2 |
|---|---|---|
| Abdominal painGastrointestinal disorders | 1/8 | 0/9 |
| EnteritisGastrointestinal disorders | 1/8 | 0/9 |
| Gastric haemorrhageGastrointestinal disorders | 1/8 | 0/9 |
| Intestinal sepsisInfections and infestations | 1/8 | 0/9 |
| PneumoniaInfections and infestations | 1/8 | 0/9 |
| Alanine aminotransferase increasedInvestigations | 1/8 | 0/9 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/8 | 0/9 |
| Oesophageal obstructionGastrointestinal disorders | 0/8 | 1/9 |
| PyrexiaGeneral disorders | 0/8 | 1/9 |
| COVID-19 pneumoniaInfections and infestations | 0/8 | 1/9 |
| Event | Paclitaxel 60 mg/m^2 | Paclitaxel 80 mg/m^2 |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 4/8 | 8/9 |
| NauseaGastrointestinal disorders | 2/8 | 7/9 |
| FatigueGeneral disorders | 2/8 | 7/9 |
| Peripheral sensory neuropathyNervous system disorders | 1/8 | 7/9 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 2/8 | 6/9 |
| NeutropeniaBlood and lymphatic system disorders | 1/8 | 5/9 |
| StomatitisGastrointestinal disorders | 2/8 | 5/9 |
| RashSkin and subcutaneous tissue disorders | 4/8 | 0/9 |
| ConstipationGastrointestinal disorders | 3/8 | 4/9 |
| VomitingGastrointestinal disorders | 1/8 | 4/9 |
The full analysis set included all participants who received any amount of any study drug.
| Age, Continuous(Years) | Paclitaxel 60 mg/m^2 | Paclitaxel 80 mg/m^2 | Total |
|---|---|---|---|
| Mean | 53.6 ± 9.5 | 57.6 ± 8.9 | 55.7 ± 9.2 |
| Sex: Female, Male(Participants) | Paclitaxel 60 mg/m^2 | Paclitaxel 80 mg/m^2 | Total |
|---|---|---|---|
| Female | 0 | 1 | 1 |
| Male | 8 | 8 | 16 |
| Ethnicity (NIH/OMB)(Participants) | Paclitaxel 60 mg/m^2 | Paclitaxel 80 mg/m^2 | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 8 | 9 | 17 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Paclitaxel 60 mg/m^2 | Paclitaxel 80 mg/m^2 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 5 | 4 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 3 | 5 | 8 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2021 to primary completion in Apr 2024, 36 months.
Results were first posted in Jan 2025, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tucatinib